Clinical Trial Update: Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating amikacin liposome inhalation suspension (ALIS) for nontuberculous mycobacterial lung infection caused by Mycobacterium avium complex ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycobacterium Avium Complex Lung Disease
• Nontuberculous Mycobacterial Infection

Drugs mentioned

• ALIS (Amikacin Liposome Inhalation Suspension) (amikacin liposome inhalation suspension)

Snippet

Sponsor: Insmed Incorporated | Conditions: Mycobacterium Infections, Nontuberculous | Phase 3 | Status: COMPLETED